| Identification | Back Directory | [Name]
iRGD | [CAS]
1392278-76-0 | [Synonyms]
iRGD
iRGD TFA
c(CRGDKGPDC)
L-Cysteine, L-cysteinyl-L-arginylglycyl-L-α-aspartyl-L-lysylglycyl-L-prolyl-L-α-aspartyl-, cyclic (1→9)-disulfide | [Molecular Formula]
C35H57N13O14S2 | [MOL File]
1392278-76-0.mol | [Molecular Weight]
948.04 |
| Chemical Properties | Back Directory | [density ]
1.68±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C, protect from light | [solubility ]
DMSO: Soluble: =10 mg/mlPBS (pH 7.2): Soluble: =10 mg/ml | [form ]
Solid | [pka]
2.92±0.70(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water : ≥ 50 mg/mL (52.74 mM) | [Sequence]
H-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-OH(Disulfide bridge: Cys1-Cys9) |
| Hazard Information | Back Directory | [Uses]
iRGD peptide is a 9-amino acid cyclic peptide, triggers tissue penetration of agents by first binding to αv-integrins, then proteolytically cleaved in the tumor to produce CRGDK/R to interact with neuropilin-1, and has tumor-targeting and tumor-penetrating properties. | [in vivo]
iRGD inserted in the oncolytic adenovirus ICOVIR15K (ICOVIR15K-iRGD) enhances early adenovirus dissemination through the tumor mass and elevates the antitumor effect in mice[1]. iRGD (4 mmol/kg, i.v.) in combination with 5-FU significantly suppresses the tumor growth in nude mice bearing human gastric cancer cells[2]. | [storage]
-20°C, protect from light | [References]
[1] Puig-Saus C, et al. iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy. Gene Ther. 2014 Aug;21(8):767-74. DOI:10.1038/gt.2014.52
[2] Zhang L, et al. Combination of NRP1-mediated iRGD with 5-fluorouracil suppresses proliferation, migration and invasion of gastric cancer cells. Biomed Pharmacother. 2017 Sep;93:1136-1143. DOI:10.1016/j.biopha.2017.06.103 |
|
|